Fig. 1

Upper: the spatial dose distribution of a representative patient and DVHs of the combined parotid glands for patients with (red solid lines) versus without (green dotted lines) clinically significant xerostomia defined using xerostomia score (≥ 20 point worsening in xerostomia score). Lower: the spatial dose distribution of a representative patient and DVHs of the combined lacrimal glands for patients with versus without clinically significant dry eye (≥ 2 point worsening in SESoD score). The isodose lines represent percentages of the prescription dose (30 Gy)